Geriatric and cancer-afflicted patients often experience decreased quality of life with cachexia, anemia, anorexia, and decreased activity level. We have studied the possibility that a myogenic plasmid that expresses growth hormone releasing hormone (GHRH) can prevent and/or treat these conditions. We administered plasmid to 17 geriatric and five cancer-afflicted companion dogs with an average age of 10.571.0 and 11.370.6 years at enrollment, respectively. Effects of the treatment were documented for at least 180 days post-treatment, with 10 animals followed for more than 1 year post-treatment, on average 444740 days. Treated dogs showed increased IGF-I levels, and increases in scores for weight, activity level, exercise tolerance, and appetite. No adverse effects associated with the GHRH plasmid treatment were found. Most importantly, the overall assessment of the quality of life of the treated animals increased. Hematological parameters such as red blood cell count, hematocrit, and hemoglobin concentrations were improved and maintained within their normal ranges. We conclude that intramuscular injection of a GHRH-expressing plasmid is both safe and capable of improving the quality of life in animals for an extended period of time in the context of aging and disease. The observed anabolic and hematological responses to a single dose of this plasmid treatment may also be beneficial in geriatric patients or patients with cancer-associated anemia and/or cachexia.
T he ability to deliver into the circulation specific proteins expressed from a DNA plasmid containing the corresponding DNA sequence of the proteins has the potential to change the fundamental approaches to prevention and/or treatment of disease. This novel strategy for disease treatment has continuous long-term production of the proteins at physiological levels, minimizes side effects and may have long-term beneficial effects. The longitudinal assessment of the quality of life of patients after plasmid administration is essential for further advancement of this treatment modality. 1 Clinical and preclinical studies have suggested that anabolic hormones, such as growth hormone (GH), insulin-like growth factor I (IGF-I), and IGF binding protein 3, may reverse the catabolic state associated with cachexia in patients. [2] [3] [4] Because of treatment cost, the frequency of administration, and the adverse effects of existing treatments, this hypothesis has not been adequately tested in companion animals. Administration of exogenous recombinant GH produces anabolic effects in a variety of conditions. [5] [6] [7] However, this treatment has certain disadvantages. It must be administered subcutaneously or intramuscularly as frequently as once a day over the entire treatment period. The pharmacological doses required to elicit these anabolic effects create nonphysiological hormonal peaks and troughs in the circulating hormone concentration and often lead to impaired glucose tolerance and insulin resistance. 8 Moreover, biological responses to exogenous GH are not similar to the physiologic responses that result from the combined actions of the naturally occurring multiple isoforms of this protein. 9, 10 Synthesis and secretion of growth hormone from the anterior pituitary are stimulated by growth hormonereleasing hormone (GHRH), a hypothalamic peptide hormone. Our preliminary studies in healthy dogs suggest that a single administration of a GHRH plasmid into skeletal muscle will ensure physiologic GHRH expression for several months. 11 The current study was designed to assess the ability of the plasmid-based GHRH treatment to produce beneficial effects in geriatric or cancer-afflicted companion dogs, and to assess long-term safety of the treatment regimen. We administered a muscle-specific GHRH expression plasmid to skeletal muscle, resulting in circulating levels of GHRH which induces synthesis and release of GH and IGF-I. The initial 56-day evaluation of 16 cancer dogs 12 demonstrated increased serum IGF-I concentrations, an indicator of GHRH bioactivity. This pilot study was conducted on severely debilitated geriatric and companion dogs with spontaneously occurring tumors. In this case, IGF-I levels were found to be elevated to up to more than 365 days post-treatment. For the longitudinal continuation of this study, we included dogs that could be analyzed for at least 180 days posttreatment. We have observed increases in weight, activity level, and exercise tolerance in addition to improvement and maintenance of hematological parameters. The overall long-term assessment of the treated dogs showed improvement in quality of life that was maintained throughout the study period. These results suggest a role for plasmid-mediated GHRH treatment in reversing the catabolic processes associated with aging and cancer anemia, and/or cachexia.
Materials and methods

Plasmid
The GHRH expression plasmid, pSPc5-12-HV-GHRH contains a strong synthetic muscle-specific promoter (SPc5-12) and encodes a GHRH analog (HV-GHRH), that has an extended half-life. 13, 14 Short-term responses to this plasmid in cancer-afflicted dogs has been described previously. 12 
Animal studies
In all, 17 geriatric and five cancer-afflicted companion dogs with solid tumors (one hemangioperycytoma, three adenocarcinoma, and one mast cell tumor) had an average age of 10.571.0 and 11.370.6 years at enrollment, respectively. Of these, seven weighed between 3 and 8 kg (Bichon Frisee, Miniature Schnauzer, 3 Shelties, Shih Tzu, Yorkshire Terrier), five weighed between 9 and 27 kg (Cocker Spaniel, Standard Schnauzer, Vizsla, Welsh Corgi, Whippet), and 11 weighed between 28 and 39 kg (Doberman Pinscher, German Shepherd, German Shorthaired Pointer, Greyhound, Irish Setter, four Labrador Retrievers, and two mixed breed). Effects of the treatment were documented for at least 180 days post-treatment, with 10 animals followed for more than 1 year posttreatment, on average 444740 days. The dogs were weighed and bled before plasmid injection and then at approximately days 20, 40, 60, 180, and 260 days posttreatment. Whole blood was collected in Monoject s Lavender Stopper blood collection tubes with 3.0 mg EDTA (Sherwood Medical, St Louis, MO) and submitted for CBC analysis (Antech Diagnostics, Irvine, CA). Serum was aliquoted for radioimmunoassay and biochemical analysis (Antech Diagnostics, Irvine, CA). Serum was stored at À801C prior to analysis. Biochemical analysis occurred within 48 hours after serum collection.
Hematological and biochemical parameters
The following parameters were evaluated: serum chemistry: amylase, globulin, gamma glutamyltransferase, total bilirubin, blood urea nitrogen, creatinine, total protein, albumin, direct bilirubin, serum alanine aminotransferase, serum aspartate aminotransferase, alkaline phosphatase, glucose, inorganic phosphorus, chloride, calcium, sodium, potassium, triglyceride, and cholesterol; hematology: erythrocyte counts, hematocrit, hemoglobin, total leukocyte count, and differential leukocyte counts (neutrophils, lymphocytes, monocytes, eosinophils, and basophils), platelet count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and partial prothrombin time; urinalysis: color, consistency, volume, glucose, bilirubin, ketone (acetoacetic acid), specific gravity, blood, pH, protein, urobilinogen, nitrite, leukocytes, and microscopic examination of formed elements.
Insulin-like growth factor-I radioimmunoassay Dog IGF-I was measured by a heterologous human assay (Diagnostic System Lab., Webster, TX). The sensitivity limit of the assay was 0.8 ng/ml; the intra-and interassay variations were 3.4 and 4.5%, respectively.
Quality of life
Evaluation of each dog's quality of life was based on the owner's response to a questionnaire completed at each visit to the attending veterinarian (see Tables 1, 2 , 4, and 5). A scoring system was developed, following the model of the Karnofsky scale modified for veterinary use, 15 for subsequent analyses of the quality of life data: 5 ¼ significantly increased (able to perform better than immediately predisease level), 4 ¼ increased (able to perform at predisease level), 3 ¼ no change (decreased activity from predisease level, but able to function as an acceptable pet), 2 ¼ decreased (ambulatory only to the point of eating and consistently defecating and urinating in acceptable areas), 1 ¼ significantly decreased (must be force-fed; unable to confine urinations and defecations to acceptable areas). Not all owners completed the required forms at all time points.
Intramuscular delivery of plasmid DNA
The endotoxin-free plasmid (Qiagen Inc., Chatsworth, CA) preparation of pSPc5-12-HV-GHRH was diluted in water to 5 mg/ml. Dogs were on active radiotherapy or chemotherapy protocols, and they were injected with the plasmid before any anticancer treatment. For dogs on chemotherapy, the injection was administered at no fewer than 5 days before or after the chemotherapy. No animal was directly irradiated on or around the injection site. The dogs were anesthetized with Propofol (Abbott Laboratories, Abbott Park, IL, 4-8 mg/kg) and injected with plasmid (100 mg/kg to a maximum of 1 mg) directly into the semimembranosous muscle. The cancer-afflicted dogs were injected using a 3/10 cm 3 insulin syringe and a 29 gauge 1/2'' needle (Becton-Dickinson, Franklin Lacks, NJ). The geriatric animals were injected using a 1 cm 3 tuberculin syringe and a 26 gauge 1'' needle. At 2 minutes after injection, the injected muscle was electroporated (5 pulses, 100 V/cm, 52 ms/pulse) with an ADViSYS electroporator, as described. 16 Animals were allowed to recover for several hours before rejoining their owners.
Statistical analysis
Data consisted of repeated measures at different time points. The Mixed Model using SAS (analysis of simple main effects) was used to examine if there are any significant differences of each variable at different time points. Mean values were compared with Students' t-test, ANOVA, or linear regression with Po.05 taken as the level of statistical significance.
Results
Five companion dogs with various spontaneously occurring malignancies and 17 geriatric dogs were enrolled in the study from January 2001 to February 2003. Long-term follow-up was performed to July 2003. As the primary focus of the experiment was to assess long-term effects of plasmid-mediated GHRH supplementation, only animals that survived for more than 180 days after treatment were included in the study. All animals were severely debilitated, as judged from weight loss, poor appetite, muscle weakness, and lethargy. The average age of dogs at enrollment in the study was 10.5 years for the cancer-afflicted and 11.3 years for disabled geriatric dogs. The tumor-bearing dogs (n ¼ 5) received standardized chemotherapy (n ¼ 2), radiotherapy (n ¼ 2), or combination chemotherapy/radiotherapy (n ¼ 1). Chemotherapy consisted of Vincristine 0.6-0.7 mg/m 2 combined with Cytoxan 200-300 mg/m 2 . Radiotherapy regimen was 80 rads to the local tumor for 16-21 visits.
Dogs were injected once in the semimembranosous muscle with the GHRH plasmid (0.1 mg/kg but less than 1 mg/animal). Plasmid uptake was enhanced by squarewave pulse electroporation. 16 Dogs were evaluated at baseline and at days 7, 20, 40, 180-365, and at 4365 days post-treatment, with an average of 188731 days from treatment to the last hematological evaluation for the cancer-afflicted dogs and 265718 days for geriatric dogs. It was not possible to acquire data for all time points tested. Quality of life questionnaires were completed throughout the study, and 10 animals (n ¼ 1 from the cancer group and n ¼ 9 from the geriatric group) monitored for 444740 days post-treatment. While in our initial evaluation on cancer-afflicted dogs, 12 we included 19 controls, only two animals survived or were made available by owners for monitoring for more than 180 days after the baseline evaluation. These could not be included in the study for statistical reasons.
Treated dogs had increased IGF-I levels from the baseline (43.271.8 ng/ml) to up to 62% of their initial IGF-I levels (70.3713.6 ng/ml) at 180 days after treatment (Po.003) (Fig 1) . At more than 365 days posttreatment, IGF-I levels were still 10% over baseline (47.476.9 ng/ml) (Po.05).
Dogs that received the GHRH plasmid exhibited increased weight scores over the course of the study, to up to 15% increase from the baseline measurements at 265 days post-treatment, (Po.001) ( Table 1 ). The appetite level score increased by 17% over the baseline measurements at 4365 days post-treatment (Po.001). The weight score was correlated with appetite score with r 2 ¼ 0.75 to day 265. Average weight was essentially constant, with decreases only from day 265 to more than 365 days post-treatment, correlating with the relative decreases in IGF-I levels between these time points. Mean scores (7SEM). Number of animals (n) and mean percentage changes relative to the pretreatment baseline score are shown.
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Exercise tolerance and activity levels were increased by 26-38 and 30-47% during the evaluation period when compared to pretreatment levels (Po.0005 and .001, respectively) ( Table 2 ). The two scores were tightly correlated throughout the study period (r 2 ¼ 0.96). Hematological parameters were evaluated separately for cancer-afflicted animals and geriatric animals. The cancer dogs showed significant long-term improvements in absolute red blood cell count, hemoglobin and hematocrit levels ( Table 3a ) that peaked at 3778 days post-treatment. These values were maintained throughout the 188731 day evaluation. Total proteins were maintained throughout the study (6.170.1 mg/ml at baseline, and 6.1570.25 at the last evaluation). Geriatric dogs showed relatively smaller increases in hematological parameters, but those changes were still maintained for the 255727 day evaluation (Table 3b) . Total serum protein levels were also increased in the geriatric dogs throughout the study. In all cases, values were within the normal physiological range. All other hematological and biochemical parameters, including glucose levels, were within the normal reference laboratory range and not indicative of any abnormality.
The overall quality of life was improved starting at day 7 post-treatment to 4365 days post-GHRH treatment (P o.002) ( Table 4) .
Furthermore, several undesired side effects of radiotherapy and/or chemotherapy treatment, or of aging cachexia were ameliorated by the GHRH treatment. The frequency of diarrhea, vomiting, and urination were decreased both in the short-and long-term evaluations after plasmid administration (Table 5) .
There were no reports of local or systemic adverse effects from plasmid-mediated GHRH administration by either the investigators or the dog owners. There were no geriatric dogs that developed tumors after treatment. Cancer-afflicted dogs were under specific cancer therapy, but did not have any reported new tumors. All respondents to the quality of life survey post-treatment noted improvement in the energy, alertness, appetite, and general well-being of their dogs.
Discussion
An ideal plasmid-based approach for the treatment or prevention of disease would utilize a minimally invasive procedure for gene delivery, have minimal associated morbidity, result in long-term transgene expression, and produce target protein levels in the therapeutic range. Only long-term follow-up can provide unique evidence supporting the safety of gene or cell-mediated transfer. 17, 18 Studying the effects of plasmid-mediated GHRH supplementation in companion dogs with spontaneously occurring cancer-or geriatric-associated pathology has advantages over conventional laboratory models. In particular, the animal population and the tumors are genetically heterogeneous, as is the case with randomly selected human patients. Thus, this study is inherently advantageous compared to studies using rodents with transplantable tumors or to inbred animals with chemically induced pathology. Another benefit is that the doses of GHRH plasmid given to dogs are comparable to those that could be used in humans. An obvious limitation of this type of study is that the dogs cannot be as intensively or invasively monitored as laboratory animals. Nonetheless, sufficient hematological, biochemical, and clinical data were available in this study to support the conclusion that the GHRH plasmid treatment is safe and beneficial long-term for dogs with geriatric-related disorders or spontaneously occurring tumors.
Following direct intramuscular injection of the plasmid, we used electroporation to enhance the uptake of plasmid by skeletal muscle cells. Given under anesthesia, this electrical enhancement is mild, requires only low plasmid doses to be effective, 19 and has been used widely and successfully to deliver plasmids to animals. [20] [21] [22] 14 Neither the investigators in this study nor the owners of the dogs reported any distress or adverse events associated with the use of this delivery method.
Cachexia and a diminished quality of life with reduced activity and appetite may, directly or indirectly, shorten the survival of geriatric and cancer patients. To test the safety and potential long-term therapeutic effect of Mean scores (7SEM). Number of animals (n) and mean percentage changes relative to the pretreatment baseline score are shown.
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GHRH expressed by a myogenic plasmid in this pathophysiological context, we administered the plasmid once intramuscularly to severely debilitated geriatric dogs or to dogs with spontaneously occurring tumors. Most of the animals (75%) showed a physiological increase in serum IGF-I concentration. 12 Animals monitored longterm had IGF-I levels that peaked at 180 days, and diminished thereafter to 365 post-treatment, but were 10% above baseline. Long-term evaluation of the quality of life parameters, including exercise tolerance and activity level scores, also showed significant improvements. Diarrhea and vomiting were significantly decreased. As noted above, there were no reported adverse effects associated with the GHRH plasmid treatment, including no reported new tumors or accelerated tumor growth.
Some of the therapeutic benefits of GHRH expression seen in these treated dogs, such as increased weight and appetite, are predicted from the effects known to result from the stimulation of the GHRH/GH/IGF-I axis in preclinical models, as lit/lit mice 23 and from studies that demonstrate the benefits of GH administration in patients with AIDS cachexia. 24 The weight gain associated with increased production of GHRH is corroborated by other studies that utilized recombinant porcine GH or GH secretagogues in dogs. 25 In one study, recombinant porcine GH was administered to dogs for 14 weeks, resulting in body weight increases of 4.7 and 2.8 kg in the high-and mid-dose groups, compared to 0.8 and 0.4 kg in the low-dose and control groups, respectively. 26 In our study, the extent of long-term improvement in both activity level and exercise tolerance, as well as the overall assessment of the quality of life of animals, was remarkable. Many owners reported behaviors comparable to those exhibited by the animals before the onset of the chronic condition. The distinct effects of plasmidmediated GHRH treatment compared to recombinant GH administration are a consequence of physiological stimulation of the GH axis rather than the effects arising from supraphysiological peaks and subphysiological troughs produced by direct injection of large doses of recombinant GH protein. This putative mechanism of GHRH action is supported by the lack of biochemical abnormalities in the plasmid-derived GHRH-supplemented animals, especially compared to with the hyperglycemia/insulin resistance observed in recipients of excessive levels of recombinant GH. 27 None of these dogs showed evidence of polycythemia following plasmid administration. The absence of this side effect indicates that this approach to stimulating the GHRH/GH/IGF-I axis restores normal physiological levels of hemoglobin and red blood cell synthesis. Indeed, some experimental dogs with normal findings prior to treatment, showed no change in hematological parameters over the study course. However, the cancerafflicted dogs with reduced hematological parameters experienced the most dramatic improvements to normalization in hemoglobin, hematocrit, and absolute red cell count, while changes were less dramatic in geriatric dogs that were not anemic at the beginning of the study. This finding confirms some studies in the literature. Long-term replacement therapy with recombinant GH in patients with adult-onset GH-deficiency induces a significant increase in hemoglobin concentrations. 28 IGF-I administration gives significant improvements in erythropoiesis in children with Laron syndrome. 29 Some patients with GH deficiency do not have anemia, but have hematopoietic precursor cells in the lower normal range. GH treatment of these subjects over a period of 24 months increased erythroid and myeloid progenitor precursor cells, with negligible effects on peripheral blood cells. 30 Furthermore, in some cases, normal dogs that received chronic injections of recombinant porcine GH developed anemia. 26 In geriatric dogs, total serum protein values were also improved, while this parameter was maintained in the cancer-afflicted dogs. In the case of cancer-afflicted dogs, Mean scores (7SEM). Number of animals (n) and mean percentage changes relative to the pretreatment baseline score are shown.
the overall improvement of quality of life was also determined by reduction in adverse effects linked to specific chemotherapy or radiotherapy, or aging cachexia, such as vomiting, diarrhea, and urination. Thus, plasmidderived GHRH exerts all of the characteristics of the naturally occurring peptide at physiological levels, while avoiding the undesirable effects of frequent injections of recombinant GH or GHRH.
Consequently, these observations demonstrate the feasibility of using plasmid GHRH to optimize GH synthesis and release in companion animals that in turn leads to the correction of catabolic processes associated with geriatric changes or cancer cachexia.
This proof-of-principle pilot study addresses a major problem in medical practice, the diminution of the quality of life of geriatric and cancer-afflicted patients, and proposes a means by which this debilitated state might be reversed. The anabolic effects that we observed following injection of a GHRH plasmid is predicted to be of value in veterinary and, eventually, human patients.
